Skip to content


  • Add this article to your LinkedIn page
  • Add this article to your Twitter feed
  • Add this article to your Facebook page
  • Email this article
  • View or print a PDF of this page
  • Share further
  • Add this article to your Pinterest board
  • Add this article to your Google page
  • Share this article on Reddit
  • Share this article on StumbleUpon
  • Bookmark this page

Exacsys, a PA Consulting Group company, publishes clinical evaluation results on how its technology can improve accuracy of Blood Glucose Monitoring  


Exacsys, a PA Consulting Group company, has published the results of a clinical evaluation in the Journal of Diabetes Science and Technology showing how its innovative low-cost technology can improve accuracy of Blood Glucose Monitoring.   

To access the article, please click here

It is estimated by the International Diabetes Federation that 382 million people in the world are living with diabetes. Self-monitoring of blood glucose (SMBG) is recommended as an integral component of diabetes therapy and studies have shown that its use is linked to better clinical outcomes and more effective control of blood glucose levels, reducing the risk of diabetes related complications.

For SMBG to play a useful role in diabetes management, three criteria should be satisfied: (i) results generated by the test are a close approximation of the true value (the system is accurate and precise); (ii) the system is convenient for the user, encouraging an appropriate frequency of testing since SMBG is consistently practised less than is recommended by commonly supported guidelines; and (iii) the overall cost of testing is aligned to the benefits accrued.

People with diabetes, clinicians and regulatory bodies have been demanding improved accuracy in SMBG and recently the required performance standards for systems to reach market have been raised. However, better performance has to be delivered at low cost, as the number of people with diabetes increases and healthcare budgets are becoming ever more stretched.

Exacsys has developed and clinically demonstrated a technology to improve accuracy of SMBG, using a low-cost approach. In this approach, each and every test is individually calibrated, rather than relying on an average factory-set calibration. Our aim is that the technology will enable high-accuracy, low-cost SMBG systems based on existing strip designs and manufacturing infrastructure. Additionally, the technology is applicable to other Self-Tests and Point-of-Care Tests and we are pursuing these applications alongside SMBG.


To find out more about Exacsys and its technology for improving accuracy of Blood Glucose Monitoring, please contact us now.

Contact the technology innovation team

By using this website, you accept the use of cookies. For more information on how to manage cookies, please read our privacy policy.